Meningioma biology and new therapies guided by molecular profiling
Official title: Project 2: Biological mechanisms and therapeutic vulnerabilities underlying meningioma evolution and heterogeneity
Funded at University of California, San Francisco · NIH-11413786 · Data updated 2026-11-12
A large, multi-institution study is exploring how meningiomas grow and respond to treatment, using advanced molecular profiling to find safer, more effective ways to manage them.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | July 1, 2007 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $480,584 |
| NIH project number | 5P01CA118816-18 |
| Project ID | NIH-11413786 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with meningioma (benign or higher grade) whose tumors have been profiled or could be profiled using molecular techniques.
✕Less likely to help
Patients whose tumors do not fit the defined molecular subgroups or who do not undergo molecular profiling may see no direct benefit.
What this research studies
This project looks at the biology of meningiomas by analyzing DNA methylation, gene expression, and other molecular features from thousands of tumor samples. The goal is to identify which tumors are more likely to recur or respond to therapies like surgery, radiotherapy, or cell-cycle–targeted drugs. By integrating data from many centers, researchers aim to improve risk prediction and tailor treatments to individual tumors. The work combines cutting-edge genomics with clinical insights to uncover actionable vulnerabilities in meningiomas.
Why it matters
Potential benefit: If successful, patients could receive more precise risk assessments and personalized treatment plans that improve outcomes and reduce unnecessary therapies.
How similar studies have gone: Prior molecular profiling studies have shown improved risk stratification and therapy guidance in meningiomas, supporting this approach.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Raleigh, David R — University of California, San Francisco
- Study coordinator: Raleigh, David R
Related research
Other NIH-funded projects on the same topics.
-
Biomarker-based guidance to predict meningioma outcomes and radiotherapy response
A gene-based test is being developed to help predict how meningioma tumors will behave and how patients may respond to radiotherapy.
-
Meningioma radiotherapy response: understanding gene clues and how to tailor treatment
A short research project will study why some meningioma tumors respond differently to radiotherapy by looking at gene activity and how it affects treatment outcomes.
-
Genomic and biochemical clues behind meningioma race differences and outcomes
This grant aims to uncover biological and environmental factors that cause differences in meningioma occurrence and treatment results across racial groups, with the goal of improving care for patients affected by this brain tumor.
-
How the MN1 protein drives aggressive acute myeloid leukemia
This project looks at how the MN1 protein and its partner BAF complex keep leukemia genes active in people with acute myeloid leukemia to reveal new treatment targets.
-
How meningiomas change over time and new treatment targets
This project looks for molecular signs that predict which meningiomas will come back and finds drug targets to help people with aggressive or recurrent tumors.
-
Finding new ways to treat meningioma brain tumors
This project looks for new medicine targets to help patients with meningioma, a common type of brain tumor.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.